Simplify Logo

Full-Time

Vice President

Regulatory Affairs

Confirmed live in the last 24 hours

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Healthcare
Biotechnology

Expert

Boston, MA, USA

Office located at 201 Brookline Avenue, Fenway area, Boston, Massachusetts.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree in life sciences, biochemistry, chemistry, biology or related pharmaceutical fields including biochemical engineering; advanced degree is desirable
  • Minimum 15 years of relevant biopharmaceutical industry experience, with at least 10 years' experience in Regulatory Affairs and deep experience in oncology; precision medicine given preference
  • Experience interacting with regulatory health authorities and experience with submitting CTA/IND and BLA/MAA filings, ideally in an area related to oncology
  • Familiarity with Chemistry, Manufacturing, and Control (CMC), Pharmacovigilance and Quality, related matters, and their intersection with Regulatory Affairs
  • Strong knowledge of drug and small molecule development regulations and guidelines including ICH, FDA, and EMA
  • Excellent written and verbal communication skills, strong technical knowledge, including regulatory writing
  • Strong leadership qualities including strategic thinking, innovation, mentoring, collaboration, etc
  • Solid working knowledge of drug development process and regulatory requirements in US and EU, Japan, Canada, and ROW a plus
  • Detail oriented; science-based reasoning skills
  • Ability to work in a fast-paced, start-up environment
  • Ability to work effectively in a collaborative team-oriented environment
  • Independently motivated and results oriented
Responsibilities
  • You will provide global regulatory leadership to support development of multiple, innovative therapies for oncology
  • Maintain, manage, and develop a high performing regulatory team
  • You will partner with key team members to develop strategies to advance our molecules from IND through pivotal studies and registration, leveraging a deep understanding of the landscape of precision oncology
  • Drive the planning and implementation of meetings with regulatory authorities and effectively represent Tango with regulatory interactions
  • Understand and interpret complex scientific issues for assigned projects as they relate to regulatory requirements and strategy for assigned projects, and provide knowledge and expertise to guide the team in appropriate regulatory strategy
  • Proactively identify regulatory issues; offer creative solutions and strategies, including risk mitigation
  • Manage and implement planning, authoring, and submission of high-quality briefing documents and clinical trial applications in the US, EU, Japan, and ROW
  • Accountable for all submissions and approvals for assigned project(s)
  • Direct point of contact with health authorities, lead and manage FDA/global health authority interactions/meetings for project responsibilities; prepare and submit responses to queries
  • Drive adherence to global regulatory guidelines relevant for the development of oncology products; author, review, and approve, as necessary, internal documentation to ensure conformance with regulations and existing regulatory approvals
  • Partner and work closely with Nonclinical, CMC, Quality, and Clinical to ensure achievement of submission deadlines, and obtain timely approvals of clinical trial applications
  • Monitor global regulatory guidelines and anticipate trends that may impact the regulatory environment to strengthen product development plan(s) and adopt regulatory strategies in a timely manner
  • Identify and implement processes, procedures, and systems appropriate for company size and stage
  • Provide Regulatory assessment to due diligence teams in terms of risks, requirements, and opportunities associated with collaborations
  • Additional duties and responsibilities as required

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies. They collaborate with larger firms, like Gilead Sciences, to co-develop therapies, which helps them secure funding and speed up the development process. Their goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Stage

IPO

Total Funding

$537M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

8%

1 year growth

20%

2 year growth

85%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tango's recent $80 million private placement financing strengthens their financial position and supports ongoing R&D efforts.
  • The company's ability to secure Orphan Drug Designation and Fast Track Designation for their therapies highlights their potential to bring innovative treatments to market quickly.
  • Participation in high-profile investor conferences and scientific meetings enhances Tango's visibility and credibility in the biotech community.

What critics are saying

  • The discontinuation of the TNG348 program due to liver toxicity raises concerns about the safety and viability of their drug candidates.
  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a leading position.

What makes Tango Therapeutics unique

  • Tango Therapeutics leverages the principle of synthetic lethality to develop cancer treatments, a unique approach that specifically targets cancer cells while sparing healthy ones.
  • Their strategic collaborations with larger pharmaceutical companies like Gilead Sciences provide financial support and accelerate the development and commercialization of their therapies.
  • Tango's robust pipeline and focus on precision oncology, including targeting MTAP-deleted solid tumors and BRCA1/2 mutations, set them apart in the oncology market.